Phase II multicentre study assessing the efficacy of Cabazitaxel in Patients with HER2-negative metastatic breast cancer and having unresectable brain metastases.

Trial Profile

Phase II multicentre study assessing the efficacy of Cabazitaxel in Patients with HER2-negative metastatic breast cancer and having unresectable brain metastases.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Cabazitaxel (Primary)
  • Indications Brain metastases; Breast cancer
  • Focus Therapeutic Use
  • Acronyms CiPHER
  • Most Recent Events

    • 17 Dec 2015 Accrual to date is 2% according to United Kingdom Clinical Research Network.
    • 24 Oct 2015 Accrual to date is 1% according to United Kingdom Clinical Research Network.
    • 08 Feb 2015 Accrual to date is 0% according to United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top